Tiova Rotacap is a long-acting muscarinic antagonist (LAMA) inhalational therapy designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It contains the active ingredient Tiotropium Bromide, which works by relaxing the muscles around the airways, helping to keep them open and making breathing easier. This medication is specifically formulated for use with the Rotahaler device, ensuring efficient drug delivery directly to the lungs. It is indicated for long-term, once-daily management to reduce exacerbations and improve quality of life in patients with COPD, including chronic bronchitis and emphysema.

Features

• Active ingredient: Tiotropium Bromide
• Strength: 18 mcg per capsule
• Delivery system: Dry powder inhaler (Rotahaler device)
• Dosage form: Hard gelatin capsules containing powder for inhalation
• Frequency: Once-daily dosing
• Mechanism: Long-acting muscarinic antagonist (LAMA)
• Onset of action: Within 30 minutes
• Duration of action: 24 hours

Benefits

• Provides sustained bronchodilation for 24 hours with once-daily dosing
• Reduces frequency of COPD exacerbations and hospitalizations
• Improves exercise tolerance and daily activity performance
• Enhances overall lung function measurements (FEV1)
• Decreases breathlessness and nighttime symptoms
• Supports long-term disease management and quality of life

Common use

Tiova Rotacap is primarily prescribed for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). It is used in patients with chronic bronchitis and emphysema to prevent symptoms and improve lung function. The medication is not intended for immediate relief of acute bronchospasm but rather for long-term control and management of COPD symptoms. Healthcare providers may prescribe it as monotherapy or in combination with other maintenance medications depending on disease severity and patient response.

Dosage and direction

The recommended dosage is one Tiova Rotacap (18 mcg) once daily, administered at the same time each day using the Rotahaler device. The capsule should not be swallowed. To use: open the Rotahaler, insert the capsule into the chamber, close the device, pierce the capsule by pressing the buttons, breathe out completely away from the device, place mouthpiece between lips, and inhale deeply and steadily. Hold breath for 10 seconds if possible. Repeat inhalation if powder remains. Always rinse mouth with water after use to reduce dry mouth and potential oral thrush.

Precautions

Patients should be monitored for paradoxical bronchospasm; discontinue immediately if it occurs. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction. May cause dizziness or blurred vision - advise against driving or operating machinery until effects are known. Not recommended for use in children or adolescents under 18 years. Pregnancy Category C: use only if potential benefit justifies potential risk to fetus. Elderly patients may require closer monitoring due to potential increased sensitivity.

Contraindications

Hypersensitivity to tiotropium bromide, atropine or its derivatives, or any component of the formulation. Not indicated for the treatment of acute bronchospasm. Contraindicated in patients with documented hypersensitivity to milk proteins (contains lactose). Should not be used as monotherapy in patients with asthma (risk of serious adverse events); not indicated for asthma treatment.

Possible side effects

Common side effects (≥1/100): dry mouth, constipation, upper respiratory tract infection, pharyngitis, sinusitis, dyspepsia, abdominal pain, headache, chest pain, edema. Less common (≥1/1000): urinary retention, tachycardia, palpitations, glaucoma, intraocular pressure increased, blurred vision, dysphonia, oropharyngeal candidiasis, skin rash, pruritus. Rare but serious: paradoxical bronchospasm, angioedema, anaphylactic reactions, atrial fibrillation. Report any persistent or worsening symptoms to healthcare provider.

Drug interaction

May interact with other anticholinergic medications (including ipratropium, aclidinium) potentially increasing side effects. Use caution with medications that affect cardiac rhythm (antiarrhythmics, tricyclic antidepressants). Beta-blockers may reduce bronchodilator effect. Diuretics may increase risk of hypokalemia. No clinically significant interactions with methylxanthines or corticosteroids reported, but monitor patients on multiple respiratory medications. Always inform healthcare provider of all medications, including OTC drugs and supplements.

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for the missed one. Resume regular dosing schedule. Do not take more than one capsule in 24 hours. Patients should be educated on maintaining regular dosing schedule for optimal control of COPD symptoms.

Overdose

Symptoms may include dry mouth, visual disturbances, tachycardia, cardiac arrhythmias, difficulty urinating, and severe constipation. Anticholinergic overdose may cause central nervous system effects including anxiety, restlessness, and confusion. Treatment is symptomatic and supportive. Consider activated charcoal if ingested recently. ECG monitoring recommended for cardiac effects. Dialysis is not effective due to high protein binding. Contact poison control center or emergency department immediately.

Storage

Store below 30°C in a dry place. Protect from moisture and direct sunlight. Keep capsules in the original blister packaging until immediately before use. Do not store in bathroom or damp areas. Keep out of reach of children and pets. Do not use capsules that are damaged, discolored, or show signs of moisture exposure. Check expiration date before use.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment recommendations. Do not initiate or discontinue medication without medical supervision. Individual responses to medication may vary. The manufacturer and distributors are not liable for any consequences arising from the use or misuse of this information.

Reviews

Clinical studies demonstrate Tiova Rotacap significantly improves lung function (FEV1) measurements compared to placebo. Patients report sustained 24-hour bronchodilation and reduced rescue medication use. Healthcare providers note improved quality of life scores and reduced exacerbation frequency in compliant patients. Some users report dry mouth as the most common side effect, typically manageable with oral hygiene measures. Overall satisfaction rates are high among patients who adhere to proper inhalation technique and regular dosing schedule.